Posts tagged psychology

Posts tagged psychology
February 7, 2012
Researchers at The Neuro and the University of Maryland have figured out the mathematical calculations that specific neurons employ in order to inform us of our distance from an object and the 3-D velocities of moving objects and surfaces relative to ourselves.
When you are about to collide into something and manage to swerve away just in the nick of time, what exactly is happening in your brain? A new study from the Montreal Neurological Institute and Hospital – The Neuro, McGill University shows how the brain processes visual information to figure out when something is moving towards you or when you are about to head into a collision. The study, published in the Proceedings of the National Academy of Sciences (PNAS), provides vital insight into our sense of vision and a greater understanding of the brain.
Researchers at The Neuro and the University of Maryland have figured out the mathematical calculations that specific neurons employ in order to inform us of our distance from an object and the 3D velocities of moving objects and surfaces relative to ourselves. Highly specialized neurons located in the brain’s visual cortex, in an area known as MST, respond selectively to motion patterns such as expansion, rotation, and deformation. However, the computations underlying such selectivity were unknown until now.
Using mathematical models and sophisticated recording techniques, researchers have discovered how individual MST neurons function. “Area MST is typical of high-level visual cortex, in that information about important aspects of vision can be seen in the firing patterns of single neurons. A classic example is a neuron that only fires when the subject is looking at the image of a particular face. This type of neuron has to gather information from other neurons that are selective to simpler features, like lines, colors, and textures, and combine these pieces of information in a fairly sophisticated way,” says Dr. Christopher Pack, neuroscientist at The Neuro and senior author. “Similarly, for motion detection, neurons have to combine input from many other neurons earlier in the visual pathway, in order to determine whether something is moving toward you or just drifting past.” The brain’s visual pathway is made up of building blocks. For example, neurons in the retina respond to very simple stimuli, such as small spots of light. Further along the visual pathway, neurons respond to more complex stimulus such as straight lines, by combining inputs from neurons earlier on. Neurons further along respond to even more complex stimulus such as combinations of lines (angles), ultimately leading to neurons that can respond to, or recognize, faces and objects for example.
Source: medicalxpress.com
ScienceDaily (Feb. 7, 2012) — Parkinson’s disease researchers at the University at Buffalo have discovered how mutations in the parkin gene cause the disease, which afflicts at least 500,000 Americans and for which there is no cure.
The results are published in the current issue of Nature Communications. The UB findings reveal potential new drug targets for the disease as well as a screening platform for discovering new treatments that might mimic the protective functions of parkin. UB has applied for patent protection on the screening platform.
"This is the first time that human dopamine neurons have ever been generated from Parkinson’s disease patients with parkin mutations," says Jian Feng, PhD, professor of physiology and biophysics in the UB School of Medicine and Biomedical Sciences and the study’s lead author.
As the first study of human neurons affected by parkin, the UB research overcomes a major roadblock in research on Parkinson’s disease and on neurological diseases in general. The problem has been that human neurons live in a complex network in the brain and thus are off-limits to invasive studies, Feng explains.
"Before this, we didn’t even think about being able to study the disease in human neurons," he says. "The brain is so fully integrated. It’s impossible to obtain live human neurons to study."
But studying human neurons is critical in Parkinson’s disease, Feng explains, because animal models that lack the parkin gene do not develop the disease; thus, human neurons are thought to have “unique vulnerabilities.”
"Our large brains may use more dopamine to support the neural computation needed for bipedal movement, compared to quadrupedal movement of almost all other animals," he says. Since in 2007, when Japanese researchers announced they had converted human cells to induced pluripotent stem cells (iPSCs) that could then be converted to nearly any cells in the body, mimicking embryonic stem cells, Feng and his UB colleagues saw their enormous potential. They have been working on it ever since.
"This new technology was a game-changer for Parkinson’s disease and for other neurological diseases," says Feng. "It finally allowed us to obtain the material we needed to study this disease."
The current paper is the fruition of the UB team’s ability to “reverse engineer” human neurons from human skin cells taken from four subjects: two with a rare type of Parkinson’s disease in which the parkin mutation is the cause of their disease and two healthy subjects who served as controls.
"Once parkin is mutated, it can no longer precisely control the action of dopamine, which supports the neural computation required for our movement," says Feng.
The UB team also found that parkin mutations prevent it from tightly controlling the production of monoamine oxidase (MAO), which catalyzes dopamine oxidation.
"Normally, parkin makes sure that MAO, which can be toxic, is expressed at a very low level so that dopamine oxidation is under control," Feng explains. "But we found that when parkin is mutated, that regulation is gone, so MAO is expressed at a much higher level. The nerve cells from our Parkinson’s patients had much higher levels of MAO expression than those from our controls. We suggest in our study that it might be possible to design a new class of drugs that would dial down the expression level of MAO."
He notes that one of the drugs currently used to treat Parkinson’s disease inhibits the enzymatic activity of MAO and has been shown in clinical trials to slow down the progression of the disease.
Parkinson’s disease is caused by the death of dopamine neurons. In the vast majority of cases, the reason for this is unknown, Feng explains. But in 10 percent of Parkinson’s cases, the disease is caused by mutations of genes, such as parkin: the subjects with Parkinson’s in the UB study had this rare form of the disease.
"We found that a key reason for the death of dopamine neurons is oxidative stress due to the overproduction of MAO," explains Feng. "But before the death of the neurons, the precise action of dopamine in supporting neural computation is disrupted by parkin mutations. This paper provides the first clues about what the parkin gene is doing in healthy controls and what it fails to achieve in Parkinson’s patients."
He noted in this study that these defects are reversed by delivering the normal parkin gene into the patients’ neurons, thus offering hope that these neurons may be used as a screening platform for discovering new drug candidates that could mimic the protective functions of parkin and potentially even lead to a cure for Parkinson’s.
While the parkin mutations are only responsible for a small percentage of Parkinson’s cases, Feng notes that understanding how parkin works is relevant to all Parkinson’s patients. His ongoing research on sporadic Parkinson’s disease, in which the cause is unknown, also points to the same direction.
Source: ScienceDaily
ScienceDaily (Feb. 7, 2012) — Each part of the body has its own nerve cell area in the brain -we therefore have a map of our bodies in our heads. The functional significance of these maps is largely unclear. What effects they can have is now shown by RUB neuroscientists through reaction time measurements combined with learning experiments and “computational modelling.” They have been able to demonstrate that inhibitory influences of neighbouring “finger nerve cells” affect the reaction time of a finger. The fingers on the outside — i.e. the thumb and little finger — therefore react faster than the middle finger, which is exposed to the “cross fire” of two neighbours on each side. Through targeted learning, this speed handicap can be compensated.
The working group led by PD Dr. Hubert Dinse (Neural Plasticity Lab at the Institute for Neuroral Computation) report in the current issue of PNAS.
Thumb and little finger are the quickest
The researchers set subjects a simple task to measure the speed of decision: they showed them an image on a monitor that represented all ten fingers. If one of the fingers was marked, the subjects were to press a corresponding key as quickly as possible with that finger. The thumb and little finger were the fastest. The middle finger brought up the rear. “You might think that this has anatomical reasons or depends on the exercise” said Dr Dinse, “but we were able to rule that out through further tests. In principle, each finger is able to react equally quickly. Only in the selection task, the middle finger is at a distinct disadvantage.”
Computer simulation depicts brain maps
To explain their observations, the researchers used computer simulations based on a so-called mean-field model. It is especially suited for modelling large neuronal networks in the brain. For these simulations, each individual finger is represented by a group of nerve cells, which are arranged in the form of a topographic map of the fingers based on the actual conditions in the somatosensory cortex of the brain. “Adjacent fingers are adjacent in the brain too, and thus also in the simulation,” explained Dr. Dinse. The communication of the nerve cells amongst themselves is organised so that the nerve cells interact through mutual excitation and inhibition.
Inhibitory influences from both sides slow down the middle finger
The computer simulations showed that the longer reaction time of the middle finger in a multiple choice task is a consequence of the fact that the middle finger is within the inhibition range of the two adjacent fingers. The thumb and little finger on the other hand only receive an inhibitory effect of comparable strength from one adjacent finger each. “In other words, the high level of inhibition received by the nerve cells of the middle fingers mean that it takes longer for the excitement to build up — they therefore react more slowly” said Dr. Dinse.
Targeted reduction of the inhibition through learning
From the results of the computer simulation it can be concluded that weaker inhibition from the neighbouring fingers would shorten the reaction time of the middle finger. This would require a so-termed plastic change in the brain — a specialty of the Neural Plasticity Lab, which has been studying the development of learning protocols that induce such changes for years. One such protocol is the repeated stimulation of certain nerve cell groups, which the laboratory has already used in many experiments. “If, for example, you stimulate one finger electrically or by means of vibration for two to three hours, then its representation in the brain changes” explained Dr. Dinse. The result is an improvement in the sense of touch and a measurable reduction of the inhibitory processes in this brain area. This also results in the enlargement of the representation of the finger stimulated.
Second experiment confirms the prediction
The Bochum researchers then conducted a second experiment in which the middle finger of the right hand was subjected to such stimulation. The result was a significant shortening of the reaction time of this finger in the selection task. “This finding confirms our prediction” Dr. Dinse summed up. Thus, for the first time, Bochum’s researchers have established a direct link between the so-called lateral inhibitory processes and decision making processes. They have shown that learning processes that change the cortical maps can have far-reaching implications not only for simple discrimination tasks, but also for decision processes that were previously attributed to the so-called “higher” cortical areas.
Source: ScienceDaily
February 6th, 2012

This STED image of a nerve cell in the upper brain layer of a living mouse shows in previously impossible detail the very fine dendritic protrusions of a nerve cell, the so-called spines, at which the synapses are located. The inset shows the mushroom-shaped head of such a dendritic spine at which the nerve cells receive information from their peers. © Max Planck Institute for Biophysical Chemistry
Source: Neuroscience News
February 6, 2012

Rock, paper or scissors? Learning while playing a strategic game against others involves a different pattern of brain activity than learning from the consequences of one’s own actions, researchers found. Credit: L. Brian Stauffer
Researchers have found a way to study how our brains assess the behavior – and likely future actions – of others during competitive social interactions. Their study, described in a paper in the Proceedings of the National Academy of Sciences, is the first to use a computational approach to tease out differing patterns of brain activity during these interactions, the researchers report.
"When players compete against each other in a game, they try to make a mental model of the other person’s intentions, what they’re going to do and how they’re going to play, so they can play strategically against them," said University of Illinois postdoctoral researcher Kyle Mathewson, who conducted the study as a doctoral student in the Beckman Institute with graduate student Lusha Zhu and economics professor and Beckman affiliate Ming Hsu, who now is at the University of California, Berkeley. "We were interested in how this process happens in the brain."
Previous studies have tended to consider only how one learns from the consequences of one’s own actions, called reinforcement learning, Mathewson said. These studies have found heightened activity in the basal ganglia, a set of brain structures known to be involved in the control of muscle movements, goals and learning. Many of these structures signal via the neurotransmitter dopamine.
"That’s been pretty well studied and it’s been figured out that dopamine seems to carry the signal for learning about the outcome of our own actions," Mathewson said. "But how we learn from the actions of other people wasn’t very well characterized."
Researchers call this type of learning “belief learning.”
To better understand how the brain processes information in a competitive setting, the researchers used functional magnetic resonance imaging (fMRI) to track activity in the brains of participants while they played a competitive game, called a Patent Race, against other players. The goal of the game was to invest more than one’s opponent in each round to win a prize (a patent worth considerably more than the amount wagered), while minimizing one’s own losses (the amount wagered in each trial was lost). The fMRI tracked activity at the moment the player learned the outcome of the trial and how much his or her opponent had wagered.
A computational model evaluated the players’ strategies and the outcomes of the trials to map the brain regions involved in each type of learning.
"Both types of learning were tracked by activity in the ventral striatum, which is part of the basal ganglia," Mathewson said. "That’s traditionally known to be involved in reinforcement learning, so we were a little bit surprised to see that belief learning also was represented in that area."
Belief learning also spurred activity in the rostral anterior cingulate, a structure deep in the front of the brain. This region is known to be involved in error processing, regret and “learning with a more social and emotional flavor,” Mathewson said.
The findings offer new insight into the workings of the brain as it is engaged in strategic thinking, Hsu said, and may aid the understanding of neuropsychiatric illnesses that undermine those processes.
"There are a number of mental disorders that affect the brain circuits implicated in our study," Hsu said. "These include schizophrenia, depression and Parkinson’s disease. They all affect these dopaminergic regions in the frontal and striatal brain areas. So to the degree that we can better understand these ubiquitous social functions in strategic settings, it may help us understand how to characterize and, eventually, treat the social deficits that are symptoms of these diseases."
Provided by University of Illinois at Urbana-Champaign
Source: medicalxpress.com
February 6, 2012
A pioneering therapy that uses magnetic pulses to stimulate the brain to treat conditions such as Parkinson’s disease, depression, schizophrenia, epilepsy and stroke is now better understood thanks to researchers from The University of Western Australia and the Université Pierre et Marie Curie in France.
Research Associate Professor Jennifer Rodger from UWA’s School of Animal Biology said she and her team tested the therapy - known as repetitive transcranial magnetic stimulation (rTMS) - on mice to find out how it can be applied to treating human neurological disease.
The research was published recently in the prestigious journal FASEB.
"Our work demonstrated for the first time that pulsed magnetic fields promote changes in brain chemicals that correct abnormal brain connections, resulting in improved behaviour and brain function," joint lead author Dr Rodger said.
"rTMS is an exciting therapy that stimulates the brain. It has shown promising results in treating the damaged human brain. Our research helps to explain how this therapy works on the cells of the brain. Previously, evidence of its usefulness was mainly from anecdotal clinical evidence.
"Our results greatly increase our understanding of the specific cellular and molecular events that occur in the brain during rTMS therapy. We are the first to show that changes in brain circuits underpin these beneficial effects. Our results have implications for how rTMS is used in humans to treat disease and improve brain function."
Dr Rodger explained that the structural and functional changes caused by the therapy in malfunctioning circuits were not seen in the normal healthy brain, suggesting that the therapy could have minimal side effects in humans.
Provided by University of Western Australia
Source: medicalxpress.com
February 6, 2012
(Medical Xpress) — A new magnetic therapy that treats major depression recently received a major boost when the government announced Medicare will cover the procedure in Illinois.
The treatment, called transcranial magnetic stimulation (TMS), sends short pulses of magnetic fields to the brain. TMS “is rapidly gaining momentum” said Dr. Murali Rao of Loyola University Medical Center, one of the first Chicago-area centers to offer TMS. There now are nearly 300 such centers in the United States.
At Loyola, about two-thirds of Rao’s TMS patients so far report that their depression has significantly lessened or gone away completely.
Before receiving TMS, Nan Miller had failed nine antidepressants and suffered increasingly severe cycles of depression over seven years. There were times when she couldn’t get out of bed or eat. “I just wanted to die,” she said. She had even tried electroconvulsive therapy (formerly known as electroshock) but did not want to consider that option anymore.
Miller said that a few weeks after beginning TMS treatments, she was eating lunch when she suddenly realized depression did not consume her anymore. “I could almost hear the chains breaking, the darkness lifting and the heaviness dissolving,” she said. “I feel about 10 years younger and 20 shades lighter.”
The Food and Drug Administration approved TMS in 2009 for patients who have major depression and have failed at least one antidepressant. The FDA has approved one TMS system, NeuroStar®, made by Neuronetics.
The patient reclines in a comfortable padded chair. A magnetic coil, placed next to the left side of the head, sends short pulses of magnetic fields to the surface of the brain. This produces currents that stimulate brain cells. The currents, in turn, affect mood-regulatory circuits deeper in the brain. The resulting changes in the brain appear to be beneficial to patients who suffer depression.
Each treatment lasts 35 to 40 minutes. Patients typically undergo three treatments per week for four to six weeks.
The treatments do not require anesthesia or sedation. Afterward, a patient can immediately resume normal activities, including driving. Studies have found that patients do not experience memory loss or seizures. Side effects include mild headache or tingling in the scalp, which can be treated with Tylenol.
Together, psychotherapy and antidepressants successfully treat only about one-third of patients who suffer major depression. TMS is a noninvasive treatment option now available for the other two-thirds of patients, who experience only partial relief from depression or no relief at all, Rao said.
Provided by Loyola University Health System
Source: medicalxpress.com
January 30th, 2012
The hippocampus (highlighted in fuchsia) is a key brain structure important to learning, memory and stress response. New research shows that children who were nurtured by their mothers early in life have a larger hippocampus than children who were not nurtured as much. Credit: Washington University Medical School from press release
Source: Neuroscience News
A newly available DNA-based prenatal blood test that can identify a pregnancy with Down syndrome can also identify two additional chromosome abnormalities: trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome).The test for all three defects can be offered as early as 10 weeks of pregnancy to women who have been identified as being at high risk for these abnormalities.
These are the results of an international, multicenter study published on-line today in the journal Genetics in Medicine. The study, the largest and most comprehensive done to date, adds to the documented capability (study published in Genetics in Medicine in October 2011) of the tests by examining results in 62 pregnancies with trisomy 18 and 12 pregnancies with trisomy 13.Together with the Down syndrome pregnancies reported earlier, 286 trisomic pregnancies and 1,702 normal pregnancies are included in the report.
The research was led by Glenn Palomaki, PhD, and Jacob Canick, PhD, of the Division of Medical Screening and Special Testing in the Department of Pathology and Laboratory Medicine at Women & Infants Hospital of Rhode Island and The Warren Alpert Medical School of Brown University, and included scientists at Sequenom Inc. and Sequenom Center for Molecular Medicine, San Diego, CA, and an independent academic laboratory at the University of California at Los Angeles.
The test identified 100% (59/59) of the trisomy 18 and 91.7% (11/12) of the trisomy 13 pregnancies.The associated false positive rates were 0.28 and 0.97%, respectively.Overall, testing failed to provide a clinical interpretation in 17 women (0.9%); three of these women had a trisomy 18 pregnancy.By slightly raising the definition of a positive test for chromosome 18 and 13, the detection rate remained constant, but the false positive rate could be as low as 0.1%.These findings, along with the detailed information learned from testing such a large number of samples, demonstrate that the new test will be highly effective when offered to women considering invasive testing.
“Our previous work demonstrated the ability to identify Down syndrome, the most common trisomy.These new data extend the finding to the next two most common trisomies and will allow for wider use of such testing with the ability to identify all three common trisomies,” said Dr. Palomaki.”The new DNA test can now also be offered to women identified as being as high risk for trisomy 18 or trisomy 13, as well those at high risk for Down syndrome.”
“This highly sensitive and specific DNA test has the potential to impact on couples’ decision-making,” says Dr. Canick.”A woman whose pregnancy was identified as high risk who earlier would have chosen not to have invasive diagnostic testing, might now consider the DNA test as a safe way to obtain further information, before making a final decision.”The US Centers for Disease Control and Prevention estimated in 1995 that about one in every 200 invasive diagnostic procedures will cause a pregnancy miscarriage.
Trisomy 18, also called Edwards syndrome, is a serious disorder with up to 70% of first trimester affected fetuses being spontaneously lost during pregnancies.Among those born alive, half die within a week with only 5% surviving the first year.All have serious medical and developmental problems.About 1,330 infants with trisomy 18 would be born in the US each year in the absence of prenatal diagnosis.Trisomy 13, also called Patau syndrome, is less common but equally serious.About 600 infants with trisomy 13 would be born in the US each year in the absence of prenatal diagnosis.Like Down syndrome, trisomy 18 and trisomy 13 are more common as maternal age increases.For comparison, about 7,730 Down syndrome cases would be born each year in the absence of prenatal diagnosis.Current prenatal screening tests for trisomy 18 and trisomy 13 rely on both biochemical and ultrasound markers.For more information visit the US National Library of Medicine PubMed Health.
This industry-sponsored project, awarded to Drs. Palomaki and Canick and Women & Infants Hospital in 2008, enrolled 4,500 women at 27 prenatal diagnostic centers throughout the world.Women & Infants also served as one of the enrollment centers under the direction of maternal-fetal medicine specialist and director of Perinatal Genetics, Barbara O’Brien, MD.
“It is clinically more relevant that all three trisomies can be detected by this test,” said Dr. O’Brien.”Having access to such a comprehensive, DNA-based test that can be done early in pregnancy will give us more information so that we can better guide which patients should consider diagnostic testing.”
Women & Infants Hospital has been an international center for prenatal screening research. For more than three decades, Drs. Palomaki and Canick have collaborated with others in developing and improving screening tests for Down syndrome and other fetal abnormalities.In 1988, Drs. Palomaki and Canick were involved in the development of triple marker screening. The team was able to convert its findings into prenatal screening tests now used throughout the world.Dr. Canick’s lab in 1998 was the first in the US to offer quad marker screening and in the past decade was the laboratory center for the NIH-funded FASTER Trial which compared first and second trimester screening.
Source: Neuroscience News